News headlines about Exelixis (NASDAQ:EXEL) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Exelixis earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.152526197999 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media stories that may have effected Accern’s rankings:

A number of equities analysts have weighed in on the stock. TheStreet upgraded shares of Exelixis from a “c” rating to a “b-” rating in a research report on Monday. Cowen and Company reiterated an “outperform” rating on shares of Exelixis in a research report on Thursday. William Blair reiterated an “outperform” rating on shares of Exelixis in a research report on Thursday, July 27th. Cann reiterated a “hold” rating on shares of Exelixis in a research report on Thursday, July 20th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $26.00 target price on shares of Exelixis in a research report on Thursday, August 3rd. Five investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $25.57.

Exelixis (NASDAQ EXEL) traded up 0.23% during trading on Friday, hitting $26.51. 2,021,024 shares of the stock were exchanged. The company has a 50-day moving average price of $26.12 and a 200 day moving average price of $22.29. Exelixis has a 1-year low of $10.04 and a 1-year high of $28.45. The firm has a market capitalization of $7.79 billion, a price-to-earnings ratio of 133.89 and a beta of 1.89.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.02. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The company had revenue of $99.01 million during the quarter, compared to the consensus estimate of $85.27 million. During the same period in the previous year, the company posted ($0.15) EPS. The firm’s revenue was up 173.1% on a year-over-year basis. Equities analysts predict that Exelixis will post $0.26 earnings per share for the current fiscal year.

In other Exelixis news, Director Carl B. Feldbaum sold 32,988 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $21.58, for a total value of $711,881.04. Following the completion of the transaction, the director now directly owns 52,721 shares in the company, valued at approximately $1,137,719.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Patrick J. Haley sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $18.46, for a total value of $92,300.00. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Exelixis (NASDAQ:EXEL) Earns Daily Coverage Optimism Rating of 0.18” was reported by Watch List News and is owned by of Watch List News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/exelixis-nasdaqexel-earns-daily-coverage-optimism-rating-of-0-18/1476059.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.